AI Terminal
N4 PHARMA PLC
AGM Information • Apr 3, 2023
7804_dva_2023-04-03_fcea1f42-0f16-4281-82ca-91269fe774b8.html
AGM Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1932V
N4 Pharma PLC
03 April 2023
3 April 2023
N4 Pharma plc
("N4 Pharma" or the "Company")
Result of Annual General Meeting
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed.
| Resolution | For | For% | Against | Against % | Total | Witheld votes* |
| Ordinary Resolution 1 - To receive the annual report and audited accounts for the year ended 31 December 2022 | 20,267,523 | 99.37% | 127,579 | 0.63% | 20,395,102 | 19,729 |
| Ordinary Resolution 2 - To re-elect John Chiplin as a Director of the Company | 20,004,322 | 98.08% | 390,780 | 1.92% | 20,395,102 | 19,729 |
| Ordinary Resolution 3 - To re-elect Luke Cairns as a Director of the Company | 20,165,927 | 98.88% | 229,175 | 1.12% | 20,395,102 | 19,729 |
| Ordinary Resolution 4 - To re-elect Chris Britten as a Director of the Company | 20,004,322 | 98.87% | 229,175 | 1.13% | 20,233,497 | 181,334 |
| Ordinary Resolution 5 - To re-appoint Saffery Champness LLP as the Companyʼs auditor and to authorise the Directors to determine their remuneration | 20,037,518 | 98.25% | 356,384 | 1.75% | 20,393,902 | 20,929 |
| Ordinary Resolution 6 - To authorise the Directors to allot shares | 19,996,465 | 98.36% | 333,237 | 1.64% | 20,329,702 | 85,129 |
| Special Resolution 7 - To disapply pre-emption rights | 20,003,065 | 98.39% | 326,437 | 1.61% | 20,329,502 | 85,329 |
*Please note a vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.
Enquiries:
| N4 Pharma plc | |
| Nigel Theobald, CEO | Via IFC Advisory |
| Luke Cairns, Executive Director | |
| SP Angel Corporate Finance LLP | Tel: +44(0)20 3470 0470 |
| Nominated Adviser and Joint Broker | |
| Matthew Johnson/Kasia Brzozowska (Corporate Finance) | |
| Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | |
| Turner Pope Investments (TPI) Limited | Tel: +44(0)20 3657 0050 |
| Joint Broker | |
| Andy Thacker James Pope |
|
| IFC Advisory Ltd | Tel: +44(0)20 3934 6630 |
| Financial PR | |
| Graham Herring | |
| Zach Cohen | |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through preclinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGBXGDSIGGDGXX